Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Curcuminoids as EBV Lytic Activators for Adjuvant Treatment in EBV-Positive Carcinomas.

Ramayanti O, Brinkkemper M, Verkuijlen SAWM, Ritmaleni L, Go ML, Middeldorp JM.

Cancers (Basel). 2018 Mar 22;10(4). pii: E89. doi: 10.3390/cancers10040089.

2.

Cytolytic virus activation therapy and treatment monitoring for Epstein-Barr virus associated nasopharyngeal carcinoma in a mouse tumor model.

Novalić Z, Verkuijlen SAWM, Verlaan M, Eersels JLH, de Greeuw I, Molthoff CFM, Middeldorp JM, Greijer AE.

J Med Virol. 2017 Dec;89(12):2207-2216. doi: 10.1002/jmv.24870. Epub 2017 Aug 29.

3.

Quantitative multi-target RNA profiling in Epstein-Barr virus infected tumor cells.

Greijer AE, Ramayanti O, Verkuijlen SA, Novalić Z, Juwana H, Middeldorp JM.

J Virol Methods. 2017 Mar;241:24-33. doi: 10.1016/j.jviromet.2016.12.007. Epub 2016 Dec 16.

4.

Epstein-Barr virus mRNA profiles and viral DNA methylation status in nasopharyngeal brushings from nasopharyngeal carcinoma patients reflect tumor origin.

Ramayanti O, Juwana H, Verkuijlen SA, Adham M, Pegtel MD, Greijer AE, Middeldorp JM.

Int J Cancer. 2017 Jan 1;140(1):149-162. doi: 10.1002/ijc.30418. Epub 2016 Sep 23.

5.

Sensing of latent EBV infection through exosomal transfer of 5'pppRNA.

Baglio SR, van Eijndhoven MA, Koppers-Lalic D, Berenguer J, Lougheed SM, Gibbs S, Léveillé N, Rinkel RN, Hopmans ES, Swaminathan S, Verkuijlen SA, Scheffer GL, van Kuppeveld FJ, de Gruijl TD, Bultink IE, Jordanova ES, Hackenberg M, Piersma SR, Knol JC, Voskuyl AE, Wurdinger T, Jiménez CR, Middeldorp JM, Pegtel DM.

Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):E587-96. doi: 10.1073/pnas.1518130113. Epub 2016 Jan 14.

6.

Can Epstein-Barr virus DNA load in nasopharyngeal brushings or whole blood predict recurrent nasopharyngeal carcinoma in a non-endemic region? A prospective nationwide study of the Dutch Head and Neck Oncology Cooperative Group.

Stoker SD, Wildeman MA, Novalic Z, Fles R, van der Noort V, de Bree R, Braunius WW, van den Broek GB, Kreike B, Kross KW, Juwana H, Ramayanti O, Verkuijlen SA, de Boer JP, Greijer AE, Middeldorp JM, Tan IB.

Eur Arch Otorhinolaryngol. 2016 Jun;273(6):1557-67. doi: 10.1007/s00405-015-3620-y. Epub 2015 May 1.

PMID:
25929413
7.

Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma.

Stoker SD, Novalić Z, Wildeman MA, Huitema AD, Verkuijlen SA, Juwana H, Greijer AE, Tan IB, Middeldorp JM, de Boer JP.

J Cancer Res Clin Oncol. 2015 Oct;141(10):1845-57. doi: 10.1007/s00432-015-1969-3. Epub 2015 Apr 29.

PMID:
25920375
8.

Epstein-Barr virus DNA load in nasopharyngeal brushings and whole blood in nasopharyngeal carcinoma patients before and after treatment.

Adham M, Greijer AE, Verkuijlen SA, Juwana H, Fleig S, Rachmadi L, Malik O, Kurniawan AN, Roezin A, Gondhowiardjo S, Atmakusumah D, Stevens SJ, Hermani B, Tan IB, Middeldorp JM.

Clin Cancer Res. 2013 Apr 15;19(8):2175-86. doi: 10.1158/1078-0432.CCR-12-2897. Epub 2013 Mar 14.

9.

Variable EBV DNA load distributions and heterogeneous EBV mRNA expression patterns in the circulation of solid organ versus stem cell transplant recipients.

Greijer AE, Stevens SJ, Verkuijlen SA, Juwana H, Fleig SC, Verschuuren EA, Hepkema BG, Cornelissen JJ, Brooimans RA, Verdonck LF, Middeldorp JM.

Clin Dev Immunol. 2012;2012:543085. doi: 10.1155/2012/543085. Epub 2012 Dec 30.

10.

Cytolytic virus activation therapy for Epstein-Barr virus-driven tumors.

Wildeman MA, Novalic Z, Verkuijlen SA, Juwana H, Huitema AD, Tan IB, Middeldorp JM, de Boer JP, Greijer AE.

Clin Cancer Res. 2012 Sep 15;18(18):5061-70. doi: 10.1158/1078-0432.CCR-12-0574. Epub 2012 Jul 3.

11.

Conserved mutation of Epstein-Barr virus-encoded BamHI-A Rightward Frame-1 (BARF1) gene in Indonesian nasopharyngeal carcinoma.

Hutajulu SH, Hoebe EK, Verkuijlen SA, Fachiroh J, Hariwijanto B, Haryana SM, Stevens SJ, Greijer AE, Middeldorp JM.

Infect Agent Cancer. 2010 Sep 19;5:16. doi: 10.1186/1750-9378-5-16.

12.

Aberrant Epstein-Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription.

Stevens SJ, Smits PH, Verkuijlen SA, Rockx DA, van Gorp EC, Mulder JW, Middeldorp JM.

AIDS. 2007 Oct 18;21(16):2141-9.

PMID:
18090040
14.

Noninvasive diagnosis of nasopharyngeal carcinoma: nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA.

Stevens SJ, Verkuijlen SA, Hariwiyanto B, Harijadi, Paramita DK, Fachiroh J, Adham M, Tan IB, Haryana SM, Middeldorp JM.

Int J Cancer. 2006 Aug 1;119(3):608-14.

15.
16.
17.

Supplemental Content

Loading ...
Support Center